CD8A and non-small cell lung carcinoma: The authenticity of the model in reflecting the physiological function of TME in ICI treatment was indicated by our finding that the activation of CD8 T cells in NSCLC-TME was dosage-dependent and that, different from cell-based in vitro assays, no antigens or cytokines are needed for the PD-1 antibody activation of CD8 T cells in the TME.32